Валеология: Здоровье, Болезнь, Выздоровление. 2019; : 66-72
ОБЗОР БЕЗОПАСНОСТИ И ЭФФЕКТИВНОСТИ ПРИМЕНЕНИЯ ФТОРХИНОЛОНОВ В ПЕДИАТРИЧЕСКОЙ ПРАКТИКЕ
Аннотация
В данном литературном обзоре представлены результаты многочисленных исследований с применением различных препаратов фторхинолонового ряда для лечения тяжелых осложнений различных инфекционных заболеваний, частоты возникновения возможных побочных эффектов и механизмы развития резистентности.
Список литературы
1. Tatsumi H., Senda H., Yatera S., Takemoto Y., Yamayoshi M., Ohnishi K. Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals. J Toxicol Sci. 1978; 3 (4) : 357–367.
2. Gough A., Barsoum N. J., Mitchell L., McGuire E. J., de la Iglesia F. A. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol. 1979; 51 (1) : 177–187.
3. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics. 2006; 118 (3) : 1287–1292.
4. Bradley J. S., Jackson M. A.; Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics. 2011; 128 (4). Available at: www.pediatrics.org/cgi/content/full/128/4/e1034
5. Patterson D. R. Quinolone toxicity: methods of assessment. Am J Med. 1991; 91 (6A) : 35S–37S.
6. Riecke K., Lozo E., Shaki Baei M., et al. Fluoroquinolone-induced lesions in the epiphyseal growth plates of immature rats. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada; September 17–20, 2000.
7. Sendzik J., Lode H., Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents. 2009; 33 (3) : 194–200.
8. US Food and Drug Administration, Division of Special Pathogen and Immunologic Drug Products. Summary of clinical review of studies submitted in a response to a pediatric written request: ciproflox-acin. Available at:www.fda.gov/downloads/drugs/ developmentapprovalprocess/ developmentresources/ucm447421.pdf. Accessed January 13, 2016
9. von Keutz E., Ruhl-Fehlert C/, Drommer W, Rosenbruch M. Effects of ciprofl oxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol. 2004; 78 (7) : 418–424.
10. Sansone J. M., Wilsman N. J., Leiferman E. M., Conway J., Hutson P., Noonan K. J. The effect of fl uoro-quinolone antibiotics on growing cartilage in the lamb model. J Pediatr Orthop. 2009; 29 (2) : 189–195.
11. Adefurin A., Sammons H., Jacqz-Aigrain E., Choonara I. Ciprofl oxacin safety in paediatrics: a systematic review. Arch Dis Child. 2011;96(9):874–880.
12. Bradley J. S., Kauffman R. E., Balis D. A., et al. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014; 134 (1). Available at: www.pediatrics.org/cgi/content/full/134/1/e146.
13. Zabraniecki L., Negrier I., Vergne P., et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol. 1996; 23 (3) : 516–520.
14. Bradley J. S., Arguedas A., Blumer J. L., Sáez-Llorens X., Melkote R., Noel G. J. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J. 2007; 26 (10) : 868–878.
15. Noel G. J., Blumer J. L., Pichichero M. E., et al. A randomized comparative study of levofloxacin versus amoxicillin / clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. Pediatr Infect Dis J. 2008; 27 (6) : 483–489.
16. Hooper D. C. Mechanisms of quinolone resistance. In: Hooper DC, Rubenstein E, eds. Quinolone Antimicrobial Agents. 3rd ed. Washington, D. C.: American Society for Microbiology Press; 2003 : 41–67.
17. Vien T. M., Minh N. N. Q., Thuong T. C., et al. The coselection of fluoroquinolone resistance genes in the gut flora of Vietnamese children. PLoS One. 2012; 7 (8) : e42919.
18. Davies T. A., Leibovitz E., Noel G. J., McNeeley D. F., Bush K., Dagan R. Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacin. Antimicrob Agents Chemother. 2008; 52 (1) : 378–381.
19. Adam H. J., Baxter M. R., Davidson R. J., et al; Canadian Antimicrobial Resistance Alliance. Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. J Antimicrob Chemother. 2013; 68 (suppl 1) : 131–137.
20. Raidt L, Idelevich E. A., Dübbers A., et al. Increased prevalence and resistance of important pathogens recovered from respiratory specimens of cystic fibrosis patients during a decade. Pediatr Infect Dis J. 2015; 34 (7) : 700–705.
21. Rose L., Coulter M. M., Chan S., Hossain J., Di Pentima M. C. The quest for the best metric of antibiotic use and its correlation with the emergence of fluoroquinolone resistance in children. Pediatr Infect Dis J.2014; 33 (6) : e158–e161.
22. Tamma P. D., Robinson G. L., Gerber J. S., et al. Pediatric antimicrobial susceptibility trends across the United States. Infect Control Hosp Epidemiol. 2013; 34 (12) : 1244–1251
Valeology: Health - Illnes - recovery. 2019; : 66-72
THE SAFETY AND EFFICIENCY’S REVIEW OF THE FLUORHINOLONES’ USE IN PEDIATRIC PRACTICE
Abstract
The review provides data on the general characteristics of fluoroquinolones and the results of side effects studies, as well as the effectiveness of this group of drugs in the treatment of severe infections in children in countries where fluoroquinolones are approved for use from an early age.
References
1. Tatsumi H., Senda H., Yatera S., Takemoto Y., Yamayoshi M., Ohnishi K. Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals. J Toxicol Sci. 1978; 3 (4) : 357–367.
2. Gough A., Barsoum N. J., Mitchell L., McGuire E. J., de la Iglesia F. A. Juvenile canine drug-induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol. 1979; 51 (1) : 177–187.
3. Committee on Infectious Diseases. The use of systemic fluoroquinolones. Pediatrics. 2006; 118 (3) : 1287–1292.
4. Bradley J. S., Jackson M. A.; Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones. Pediatrics. 2011; 128 (4). Available at: www.pediatrics.org/cgi/content/full/128/4/e1034
5. Patterson D. R. Quinolone toxicity: methods of assessment. Am J Med. 1991; 91 (6A) : 35S–37S.
6. Riecke K., Lozo E., Shaki Baei M., et al. Fluoroquinolone-induced lesions in the epiphyseal growth plates of immature rats. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada; September 17–20, 2000.
7. Sendzik J., Lode H., Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents. 2009; 33 (3) : 194–200.
8. US Food and Drug Administration, Division of Special Pathogen and Immunologic Drug Products. Summary of clinical review of studies submitted in a response to a pediatric written request: ciproflox-acin. Available at:www.fda.gov/downloads/drugs/ developmentapprovalprocess/ developmentresources/ucm447421.pdf. Accessed January 13, 2016
9. von Keutz E., Ruhl-Fehlert C/, Drommer W, Rosenbruch M. Effects of ciprofl oxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol. 2004; 78 (7) : 418–424.
10. Sansone J. M., Wilsman N. J., Leiferman E. M., Conway J., Hutson P., Noonan K. J. The effect of fl uoro-quinolone antibiotics on growing cartilage in the lamb model. J Pediatr Orthop. 2009; 29 (2) : 189–195.
11. Adefurin A., Sammons H., Jacqz-Aigrain E., Choonara I. Ciprofl oxacin safety in paediatrics: a systematic review. Arch Dis Child. 2011;96(9):874–880.
12. Bradley J. S., Kauffman R. E., Balis D. A., et al. Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin. Pediatrics. 2014; 134 (1). Available at: www.pediatrics.org/cgi/content/full/134/1/e146.
13. Zabraniecki L., Negrier I., Vergne P., et al. Fluoroquinolone induced tendinopathy: report of 6 cases. J Rheumatol. 1996; 23 (3) : 516–520.
14. Bradley J. S., Arguedas A., Blumer J. L., Sáez-Llorens X., Melkote R., Noel G. J. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J. 2007; 26 (10) : 868–878.
15. Noel G. J., Blumer J. L., Pichichero M. E., et al. A randomized comparative study of levofloxacin versus amoxicillin / clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. Pediatr Infect Dis J. 2008; 27 (6) : 483–489.
16. Hooper D. C. Mechanisms of quinolone resistance. In: Hooper DC, Rubenstein E, eds. Quinolone Antimicrobial Agents. 3rd ed. Washington, D. C.: American Society for Microbiology Press; 2003 : 41–67.
17. Vien T. M., Minh N. N. Q., Thuong T. C., et al. The coselection of fluoroquinolone resistance genes in the gut flora of Vietnamese children. PLoS One. 2012; 7 (8) : e42919.
18. Davies T. A., Leibovitz E., Noel G. J., McNeeley D. F., Bush K., Dagan R. Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacin. Antimicrob Agents Chemother. 2008; 52 (1) : 378–381.
19. Adam H. J., Baxter M. R., Davidson R. J., et al; Canadian Antimicrobial Resistance Alliance. Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals. J Antimicrob Chemother. 2013; 68 (suppl 1) : 131–137.
20. Raidt L, Idelevich E. A., Dübbers A., et al. Increased prevalence and resistance of important pathogens recovered from respiratory specimens of cystic fibrosis patients during a decade. Pediatr Infect Dis J. 2015; 34 (7) : 700–705.
21. Rose L., Coulter M. M., Chan S., Hossain J., Di Pentima M. C. The quest for the best metric of antibiotic use and its correlation with the emergence of fluoroquinolone resistance in children. Pediatr Infect Dis J.2014; 33 (6) : e158–e161.
22. Tamma P. D., Robinson G. L., Gerber J. S., et al. Pediatric antimicrobial susceptibility trends across the United States. Infect Control Hosp Epidemiol. 2013; 34 (12) : 1244–1251
